Infusion reactions triggered by monoclonal antibodies treating solid tumors

Journal of Infusion Nursing

Volumn 31, Issue 2, 2008, Pages 74-83

  Carney, Pamela H ^a,c   Ollom, Cathy L ^b  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c ONCOLOGY NURSING SOCIETY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; MONOCLONAL ANTIBODY; PACLITAXEL; PANITUMUMAB; TRASTUZUMAB;

ADJUVANT THERAPY; AIRWAY OBSTRUCTION; ANAPHYLAXIS; ARTICLE; ASTHENIA; BREAST CANCER; BRONCHOSPASM; CHILL; DIAPHORESIS; DIZZINESS; DRUG APPROVAL; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG TOLERABILITY; DYSPNEA; FEVER; HEAD AND NECK CANCER; HEADACHE; HEART ARREST; HOARSENESS; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; HYPOTENSION; IMMUNOGENICITY; INJECTION SITE REACTION; LUNG NON SMALL CELL CANCER; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; NURSING CARE; OXYGEN DESATURATION; PAIN; PATIENT ASSESSMENT; PATIENT MONITORING; PREMEDICATION; PRIORITY JOURNAL; RASH; RIGOR; SIDE EFFECT; SOLID TUMOR; STRIDOR; THORAX PAIN; URTICARIA; VOMITING; WHEEZING;

ALGORITHMS; ANTIBODIES, MONOCLONAL; DECISION TREES; DRUG HYPERSENSITIVITY; DRUG MONITORING; EMERGENCY TREATMENT; HUMANS; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; NURSE'S ROLE; NURSING ASSESSMENT; ONCOLOGIC NURSING; SEVERITY OF ILLNESS INDEX;

EID: 41049103668     PISSN: 15331458     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.NAN.0000313654.57786.bb     Document Type: Article

References (27)

1. Mellstedt H. Monoclonal antibodies in human cancer. Drugs Today (Barc). 2003;39(suppl C):1-16.
2. Weiner LM. Fully human therapeutic monoclonal antibodies. J Immunother. 2006;29(1):1-9.
3. Groner B, Hartmann C, Wels W. Therapeutic antibodies. Curr Mol Med. 2004;4(5):539-547.
4. Thomas M. Cetuximab: adverse event profile and recommendations for toxicity management. Clin J Oncol Nurs. 2005;9(3):332-338.
5. Herbst RS. Therapeutic options to target angiogenesis in human malignancies. Expert Opin Emerg Drugs. 2006;11(4):635-650.
6. Roskos LK, Davis CG, Schwab GM. The clinical pharmacology of therapeutic monoclonal antibodies. Drug Dev Res. 2004;61:108-120.
7. Weiner LM. An overview of monoclonal antibody therapy of cancer. Semin Oncol. 1999;26(suppl 12):41-50.
8. Cheng JD, Rieger PT, von Mehren M, Adams GP, Weiner LM. Recent advances in immunotherapy and monoclonal antibody treatment of cancer. Semin Oncol Nurs. 2000;16(pt 4, suppl1):2-12.
9. Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med. 2005;72(4):250-256.
10. Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov. 2003;2(1):52-62.
11. Fiola C. Monoclonal antibodies as anticancer agents. US Pharm. 2003;28(10):1-13. http://www.uspharmacist.com/index.asp?show=article&page= 8_1147.htm. Accessed March 5, 2007.
12. Weir ANC, Nesbitt A, Chapman AP, Popplewell AG, Antoniw P, Lawson ADG. Formatting antibody fragments to mediate specific therapeutic functions. Biochem Soc Trans. 2002;30(4):512-516.
13. Herceptin® (trastuzumab) [package insert]. South San Francisco, CA: Genentech Inc; 2006.
14. Avastin® (bevacizumab) [package insert]. South San Francisco, CA: Genentech Inc; 2006.
15. Erbitux® (cetuximab) [package insert]. Branchburg, NJ: Imclone Systems Inc; 2006.
16. Vectibix™ (panitumumab) [package insert] Thousand Oaks, CA: Amgen Inc; 2006.
17. Fish-Steagall A, Searcy P, Sipples R. Clinical experience with anti-EGFR therapy. Semin Oncol Nurs. 2006;22(1):10-19.
18. Frankel C. Development and clinical overview of trastuzumab (Herceptin). Semin Oncol Nurs. 2000;16(pt 4, suppl 1):13-17.
19. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events v3.0 (CTCAE). DCTD, NCI, NIH, DHHS. March 31, 2003. http://ctep.cancer.gov/forms/CTCAEv3.pdf. Published August 9, 2006. Accessed February 28, 2007.
20. Timoney JP, Eagan MM, Sklarin NT. Establishing clinical guidelines for the management of acute hypersensitivity reactions secondary to the administration of chemotherapy/biologic therapy. J Nurs Care Qual. 2003;18(1):80-86.
21. Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; and Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol. 2005;115(pt 3, suppl 2):S483-S523.
22. Khoukaz T. Administration of anti-EGFR therapy: a practical review. Semin Oncol Nurs. 2006;22(1):20-27.
23. Carr BW, Burke C. Outpatient chemotherapy: hypersensitivity and anaphylaxis. Am J Nurs. 2001;101(suppl):27-30.
24. Polovich M, White JM, Kelleher LO, eds. Chemotherapy and Biotherapy Guidelines and Recommendations for Practice. 2nd ed. Pittsburgh, PA: Oncology Nursing Society; 2005:86.
25. Tang AW. A practical guide to anaphylaxis. Am Fam Physician. 2003;68(7):1325-1332.
26. Albanell J, Baselga J. Systemic therapy emergencies. Semin. Oncol. 2000;27:347-361.
27. Gobel BH. Chemotherapy-induced hypersensitivity reactions. Oncol Nurs Forum. 2005;32(5):1027-1035.